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ExPloRing thE UsE of ValUE of infoRMation MEthods to PRioRitisE 
REsEaRch to addREss thE tREatMEnt UncERtaintiEs idEntifiEd By thE 
JaMEs lind alliancE PRioRity sEtting PaRtnERshiPs
Sach T, McManus E
University of East Anglia, Norwich, UK
Economic analysis is regularly used to inform decisions on allocating healthcare 
budgets but not routinely for allocating health research budgets which may mean 
that the research budget is not delivering value for money. The study aims to use 
‘value of information’ analysis to prioritise research funding across an entire clini-
cal area. In particular, exploring the usefulness of such methods in prioritising the 
treatment uncertainties identified by the James Lind Alliance (JLA) Priority Setting 
Partnership (PSP) for atopic eczema. Whilst the research will primarily identify what 
the future research priorities within eczema should be, it will also act as a case study 
of how such methods could be applied to JLA PSPs for other conditions. The poten-
tial benefit of this research is in reducing the first two stages of research waste (i) 
‘Questions relevant to research users?’ And (ii) ‘Appropriate research design, conduct 
and analysis?’ identified by Chalmers and Glasziou (2009). The methods proposed 
for doing the work will be described, with a focus on those stages already underway. 
This includes defining the decision problems, building on the work of the eczema 
JLA PSP, and conceptual modelling, understanding the disease process and service 
pathways for eczema with expert input. The potential usefulness and challenges of 
the approach will be discussed. Strengthening methods around research prioritisa-
tion and study design is important to ensure value for money from limited research 
funding. Reference: Chalmers I, Glasziou P. Avoidable waste in the production and 
reporting of research evidence. Lancet 2009; 374: 86-89
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UsE of a MUlti-dEcision cRitERia analysis to sUPPoRt hEalthcaRE 
dEcision-Making foR PRiVatE PayERs in BRazil: dEVEloPMEnt of a 
ModEl to gUidE REiMBURsEMEnt dEcisions
do Nascimento Junior RR1, Asano E2
1PLANSERV - Plano de Assistência à Saúde dos Servidores Públicos Estaduais, Salvador, Brazil, 
2Janssen, São Paulo, Brazil
Objectives: Although the use of cost-effectiveness analysis has been increasing in 
Brazil, there is no evidence of an appropriate willingness-to-pay value to interpret 
results. The objective of this study is to develop an alternative model to support 
reimbursement decisions of private payers in Brazil. MethOds: A value meas-
urement Multi Decision Criteria Analysis (MCDA) model was developed in order 
to reflect different dimensions that influence healthcare decisions. A literature 
review was performed in order to identify the most common criteria and scores 
scales to be included in the model, which was further complemented by expert 
opinion. Analytical hierarchy process was used to weight the importance of each 
dimension by pairwise comparisons. A group representing different stakeholders 
(academia, payer, industry, health service provider and physician) was formed in 
order to consider different perspectives when validating the final model. Results: 
A simple linear additive model with four dimensions (clinical impact, strength of the 
evidence, economic impact and feasibility of adoption) was developed based on the 
literature. After validation by expert opinion, these 4 dimensions were divided into 
a total of 10 criteria (“treatment costs”, “indication prevalence”, “level of evidence”, 
“relevance of outcome”, “impact on health”, “severity of disease”, “feasibility of 
adoption”, “legal implications”, “ethical implications” and “technology position-
ing”). Weights for each criterion were assigned, with disproportional values given to 
“legal implications” and “ethical implications”, as these were considered mandatory 
requirements. The final score was then classified into 5 options based on the likeli-
hood of recommendation. Univariate sensitivity analysis to the assigned weights 
was performed to check the robustness of the results. cOnclusiOns: The proposed 
MCDA model may provide additional support to prioritize and guide reimbursement 
decisions for individual payers in the private Health System in Brazil.
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ModElling to dEtERMinE thE PRicE and idEntify cRitical data gaPs 
dURing VaccinE dEVEloPMEnt
Davey P, Ball M
Illuminate Health Consulting, Chatswood, Australia
Objectives: A preliminary model was built early in the development pathway for a 
new vaccine. The vaccine had been studied in phase II trials but was yet to be tested 
in a phase III study. The twin objectives of the model was to determine the highest 
price for the vaccine where it remains cost effective and to identify which variables 
will most determine cost effectiveness. MethOds: A simple decision analytic model 
was built to determine the cost per QALY associated with the use of the vaccine 
in an elderly population. A literature search was undertaken to identify published 
evidence to populate the model. The model was run for a cohort equal to the total 
population in the countries for which the model was developed. This enabled the total 
budget requirement for a national vaccination program to be estimated. Results: 
The model generated a price up to $600 per course of vaccine and with a cost per 
QALY of $US50,000. The main drivers of the cost effectiveness was the frequency; cost 
per episode of care for hospital addmissions, the incremental efficacy of the vaccine 
and mortally associated with the underlying infection. cOnclusiOns: The model 
identified a number of areas which would be important for data collection, these are 
mostly related. It shows the value of early decision analytic modelling to determine 
the threshold price and the data gaps. This will help the organisation developing the 
vaccine to focus research on collecting information which will be useful when applica-
tions are being made for reimbursement of the vaccine in the future.
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can adVancEs in hEalth MonitoRs lEad to hEalth BEing lookEd at as 
a coMModity?
Focsa S
Executive Insight, Zug, SC, Switzerland
As advances in health monitors are being developed the opportunity for them to be 
integrated into daily healthcare infrastructure is also expanding. Many healthcare 
systems are facing increasing budgetary pressure and are finding it hard to make 
decisions about what treatments to cover. The willingness to pay a fair price for 
the benefits of healthcare is present; however, the current infrastructure and 
evaluation process has limitations. Patients can gain different benefits from the 
same treatments while also incurring the same cost. Drug evaluations are lengthy 
and complex processes, especially for ones that have multiple indications, sub-
populations and formulations to consider. Market restrictions of having one price 
per brand often leads to access restrictions not allowing patients to benefit fully 
from the treatments available. Furthermore, costs for non-compliant patients 
and adverse events are also upheld by current healthcare systems meaning that 
the cost per benefits are not fully realized. Continuous monitoring of patients 
could pave the way forward for scalable, accurate and effective payment by result 
systems that will allow patient benefits to be directly linked to the cost of treat-
ment. If monitors can accurately evaluate the amount of benefit each patient 
gains from treatment it can effectively remove the need for drug pricing as a 
whole, only a cost per unit of health would need to be established and healthcare 
systems would pay for the total benefits gained by the population, similar to how 
electricity is paid for using a meter. This change could allow drugs to enter markets 
with fewer restrictions and be used optimally by physicians where they feel they 
add the most benefit to patients. Furthermore, patient compliance and adverse 
events would become the financial responsibility of the drug provider, they will 
need to enforce monitoring, compliance and incentivize on-label use to provide 
the maximum patient benefits.
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a MEthod to EValUatE UncERtainty dUE to Unknown PaRaMEtER 
coRRElation in stochastic dEcision ModEls
O’Day K, Liu S, Bozkaya D
Xcenda, Palm Harbor, FL, USA
Objective: To present a method for evaluating uncertainty due to unknown 
parameter correlations in stochastic decision models. MethOds: The use of 
probabilistic sensitivity analysis (PSA) has grown significantly in health economic 
decision modeling. When parameter correlations are known various methods exist 
to evaluate uncertainty in PSAs to account for correlations (eg, Cholesky decom-
position). However, in cohort analyses, using literature-based data, parameter cor-
relations are seldom known and it is therefore typically assumed that parameters 
are uncorrelated and independent. We present a method and worked example to 
explore uncertainty due to parameter correlation in the absence of known correla-
tions. For a decision model with n parameters a n x n diagonal correlation matrix 
defining all parameter correlations is developed. With the SIMTOOLS add-in, the 
CORAND function and correlation matrix are used to generate correlated random 
numbers for the model simulation. For the base case all parameters in the matrix 
are assumed to be independent and the correlations are set to zero. Systematic 
analyses can then be conducted in which model parameters, individually or in 
groups, are correlated to explore the potential impact of parameter correlation 
on the model outcomes. We report the results of a sample analysis and show 
that parameter correlations can have a significant impact on model uncertainty. 
While the median ICERs did not change significantly, the 95% confidence intervals 
ranged widely as the shape of the ICER-scatterplots changed. Parameters with 
little impact in deterministic sensitivity analyses were observed to contribute to 
significant uncertainty in the correlation analysis. cOnclusiOns: In stochas-
tic decision models where parameter correlations are unknown, it is possible 
to evaluate uncertainty due to potential parameter correlations in Excel-based 
decision models. Unknown parameter correlations may be a significant source of 
uncertainty. Future research is needed to validate this method in comparison to 
methods for evaluating known parameter correlations.
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PRactical considERations in thE aPPlication of statistical MEthods 
foR tREatMEnt switching
Watkins CL
AstraZeneca, Macclesfield, UK
Treatment switching occurs in a clinical trial when control arm patients switch to 
experimental therapy during the study. This often happens in oncology trials where 
patients switch following disease progression, and can reduce the observed survival 
difference. An estimate of the survival effect without switching may be required for 
economic modelling, and several methods have been developed to estimate this. 
In 2014, the NICE Decision Support Unit published Technical Support Document 
(TSD) 16 to provide guidance on this. There are several practical considerations for 
the statistician or analyst wanting to apply these methods to clinical trials data. 
The analysis framework proposed in TSD16 is useful, but it can be difficult to apply 
retrospectively unless the trial was designed with this objective in mind. So are there 
any trial design features that should be included in the protocol at the start? The 
right data must be collected to enable the methods to be applied – what data is that, 
is it practical to collect it all, what should be done if not? Each method has strong 
underlying assumptions such as a constant treatment effect or no unmeasured 
confounders – how could those assumptions be assessed for viability? Several recent 
health technology assessments have tried to apply these methods and shown either 
very different results from different models, or have struggled to fit the models at 
all. Why might that be? What could the analyst do in this situation? Guidance will be 
provided on these issues based on experience of applying these methods to real-life 
data and a review of recent health technology assessments.
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MoVing BEyond thE Picos: aPPRoPRiatE coMPaRatiVE oBsERVational 
data sElEction can facilitatE MEta-analysis of RElatiVE tREatMEnt 
EffEcts
Sallum R1, Zhang Y2, Xu Y1
1Evidera, Lexington, MA, USA, 2Evidera, London, UK
Evidence synthesis based on the quantitative analysis (indirect treatment com-
parisons ITC) of data from randomized controlled trials (RCTs) is the gold standard 
in healthcare decision making. However, when ITC of RCTs may not be practical or 
possible, comparative observational data may provide a valuable alternative despite 
potential challenges with internal validity. The present project aims to develop a 
conceptual framework from which valid quantitative assessment of real-world evi-
dence (RWE) can provide necessary insights into treatment effects outside the RCT 
settings. Considerations of quantitative evidence synthesis in RWE were identified 
using published best-practice guidelines for quantitative analysis of RCT data and 
applied to two test cases, atrial fibrillation (AF) treated with novel oral anticoagulant 
(NOAC) and type II diabetes treated with antihyperglycemic agents. Data sources of 
RWE, sample selection, outcome definitions, and statistical method variation were 
assessed. Significant variations across all key factors were observed in studies for 
both indications. In the case of NOAC treated AF, homogeneity of the data source 
and geographic location did not guarantee appropriate quantitative comparison. 
Several factors unique to assessing observational database study comparability for 
meta-analyses were identified including a need for a greater focus on selection bias 
inherent to the type and location of the database and increased sensitivity of esti-
mates to the index dates particularly in relation to local and international product 
launches, as well various outcome definition and reporting complexities. Valid ITC 
could be performed using RWE from comparative observational studies. Careful 
selection of studies is required to mitigate factors that would otherwise compro-
mise results through uncontrolled bias. Researchers need to go beyond the obvious 
individual study reporting biases and fully assess the complexities of comparative 
data sources to be able to appropriately select studies for ITC.
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PUBlic consUltations: a tool foR thE inclUsion of sociEty in thE 
BRazilian hta PRocEss
Silva AS, DA Silveira LC
Brazilian Ministry of Health, Brasília, Brazil
The participation of society in HTA is crucial and needs to be implemented. In the 
last years, it has been analyzing, discussing, and questioning how to actually intro-
duce the public’s participation into HTA processes within the Brazilian Public Health 
System (SUS) perspective. In 2011, Law 12,401 was enacted, making the participation 
of civil society official within the process of incorporating technologies in the health 
system through: the participation of a representative of the National Health Council 
(CNS) on the National Committee for Health Technology Incorporation (CONITEC); 
the execution of a Public Consultation (PC) for each theme evaluated by CONITEC; 
and through a Public Hearing prior to final decision-making, in case the relevance of 
the matter should justify such a hearing. The aim of this abstract is to describe the 
activities which are being developed after a study published in 2013 which identified 
proposals for improving the mechanisms of society’s involvement in the processes 
of the assessment and incorporation of technologies into the SUS. Many of these 
proposals, among others, are being implemented by the Executive Secretariat of 
the CONITEC. Some of those proposals were to improve its disclosure and to attain 
a better use of social media. We started to disseminate information regarding PC 
through social network, website and mailing lists to the interested audiences, in 
addition to producing reports in an appropriate language for patients, which was 
another proposal made previously by the cited study. Furthermore, a new PC form 
was especially created in order to report the society’s perspective (patients, caregiv-
ers and health professionals’ experiences) and a Guide to HTA for Patients is also 
being produced. Public Consultations as a tool for the inclusion of society in HTA is 
legitimate and innovative; improve this will increase Patient and Public Involvement 
in the Brazilian HTA process.
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assEssing hEtERogEnEity acRoss gRoUPs of clinical tRials BasEd on 
aggREgatE data
Schmidt H1, Koegler H2, Geier S2, Glaab T2, Metzdorf N2
1Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany, 2Boehringer Ingelheim 
Pharma GmbH & Co KG, Ingelheim, Germany
Meta-analyses in the classical sense, comparing two treatments across clinical tri-
als, are used for information synthesis during all phases of clinical research and 
development and especially in the context of reimbursement and assessment of 
relative effectiveness. In this meta-analytic framework we examined consistency 
of the relative treatment effect between groups of trials by application of a test for 
subgroup heterogeneity using aggregate trial data. A wide variety of software for 
performing meta-analyses and testing subgroup heterogeneity can be used, rang-
ing from ready-to-use systems like the Cochrane Collaboration’s RevMan software 
to packages requiring statistical expert knowledge. We applied this software and 
illustrate examination of heterogeneity in groups of trials by several examples. 
The first example investigates heterogeneity between groups of trials comparing 
different long-acting β 2-agonists (LABAs) versus Placebo with regard to exacerba-
tions in Chronic Obstructive Pulmonary Disease (COPD). Absence of heterogeneity 
was demonstrated and, hence, it turned out that the beneficial effect of Tiotropium 
in preventing COPD exacerbations, as e.g. directly demonstrated versus the LABA 
Salmeterol in the POET-COPD©trial, can be extended versus various LABAs. The 
second example examines heterogeneity in quality of life (QoL) as measured by the 
Saint George’s Respiratory Questionnaire (SGRQ) across Placebo-controlled COPD 
trial groups where Tiotropium was administered either open-label or blinded. It 
was shown that the magnitude of response with this QoL measure is inconsistent 
between open-label and blinded administration of Tiotropium with a higher benefit 
1Velammal Medical College Hospital and Research Institute, Madurai, India, 2MarksMan 
Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India
bAckgROund: Treatments associated with excellent outcomes in a research set-
ting in randomised controlled trials (RCTs) may not be beneficial in the real-world 
settings which has a different spectrum of patients in different clinical situations. 
Therefore, healthcare providers are looking for evidence in the real-world setting in 
addition to RCTs. In this background, health insurance claims data are a source of 
invaluable real-world data. Claims data are increasingly being used for pharmaco-
economic and outcomes researchin regions like North America, Europe, Australia, 
and New Zealand. The major advantages of claims data over RCT data include: (a) 
health outcomes can be evaluated in real-world settings; (b) analysis results can 
be generalised to a broader population; (c) relatively inexpensivethan RCTs; (d) 
provide wide range of information about various conditions and procedures from 
a large number of patients, belonging to varied demographics; (e) data availability 
over extended periods of time allow retrospective cohort studies; (f) unaffected by 
recall bias; (g) large sample size will make the statistical methods more consistent. 
However, there are some limitations as well, such as incomplete diagnostic and 
provider identification data, and the fact that the population characteristics are 
largely influenced by the insurance plan, plan benefit design, and the variables 
of the database. Claims data in India are insufficiently used for health outcomes 
research. An important reason for this is that the penetration of health insurance is 
not up to the mark in India. It is expected that health insurance will become more 
popular in India, since (a) Indian health care expenditure is predominantly out-of-
pocket, and (b) the healthcare costs are escalating day-by-day. RECOMMENDATIONS: 
With the increased penetration of health insurance in India, appropriate analysis 
of the resulting claims data can provide invaluable insights into demographics, 
disease trends, efficacy and effectiveness, and real-world information, from the 
Indian perspective.
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PossiBlE aPPlications of REal woRld EVidEncE in safEty oPERations
Kaneria J, Bhutani MK, Goyal R, Rai MK
Tata Consultancy Services, Mumbai, India
Regulatory agencies are providing market authorization of pharmaceutical prod-
uct solely on the basis of efficacy, compliance and side effects derived from ran-
domised clinical trials (RCTs) which frequently fail to reflect real time use. It is 
important for the pharmaceutical companies and regulatory agencies to ensure 
that drug is performing well in the real world as it does in the closely monitored 
world of clinical trials. The payers like Medicare and Medicaid in the United States 
are also emphasizing on the drug benefits in real clinical practice. Also, the recent 
amendments in European Pharmacovigilance legislation emphasize continuous 
risk benefit assessment/risk management of pharmaceutical product following its 
launch in European market. Thereby, sources of good quality RWE will be essen-
tial for companies to meet regulatory authority expectations. The key activities 
within the area of Risk Management include compilation of Risk Management 
Plans (RMPs) and aggregate reports such as the Periodic Safety Update Report 
(PSUR), Periodic Benefit Risk Evaluation Report (PBRER), and the Development 
Safety Update Report (DSUR). These pharmacovigilance competencies can prove 
to be very useful in identifying drug’s risk-benefit profile which includes potential 
safety concerns, risk factors, effectiveness measures, safety signals, and target 
population. By leveraging database and observational studies, signal detection 
algorithms, surveys and extensive pharmacovigilance competencies, following 
research objectives can be achieved with Real World Safety evidence: Define drug 
exposure; Assess the epidemiology of indication/target population; Identify poten-
tial safety concerns and characterize known risk factors; Determine prescrib-
ing conditions/patient characteristics for drugs; Determine the effectiveness of 
measures to minimize risk; Identify and evaluate safety signals in a systemized 
way; The above mentioned concepts can serve as a precursor for planning of RWE; 
prospective and retrospective studies which can lead to potential cost saving and 
efficient analysis of the safety apprehensions.
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hUMan hEalth daMagE ModElling in lifE cyclE assEssMEnt: a 
ValUaBlE addition to thE EValUation of MEdical intERVEntions?
Debaveye S1, De Soete W1, De Meester S1, Vandijck D1, Heirman B2, Kavanagh S2, Dewulf J1
1Ghent University, Gent, Belgium, 2Johnson & Johnson, Beerse, Belgium
Current practice in Life Cycle Assessment (LCA) has, until now, focused predomi-
nantly on charting the environmental footprint of products and systems in vari-
ous industries. LCA studies typically report the environmental damage on three 
Areas of Protection: Natural Resources, Ecosystem Quality and Human Health. 
The damage results from the cause-effect chain of the use of natural resources 
and the release of emissions during the life cycle of any product. The third Area 
of Protection Human health is based on e.g. particulate matter emissions causing 
respiratory diseases and health effects related to global warming such as a higher 
incidence of food and waterborne diseases or natural disasters. These effects are 
gathered under a common unit: the Disability Adjusted Life Year (DALY), which 
accounts for both the morbidity and mortality of diseases. In the pharmaceutical 
sector, several LCA studies have evaluated different parts of the supply chain. Drug 
production, patient transport and hospital heating all contribute to the global 
environmental damage, including Human Health, of a full medical treatment. 
However, medical interventions are predominantly evaluated on their treatment 
benefits and risks in terms of how a patient feels, functions and survives. In 
addition, their costs and benefits are also weighted against each other in order 
to define the cost-effectiveness of a medical treatment. We propose the addition 
of the environmental health burden to the current evaluation methodologies of 
a medical treatment. This would allow for a more holistic appraisal, taking into 
account the effects of health care indirect resource use and emissions. The exist-
ing state of the art methodology for the quantification of environmental Human 
Health damage is discussed.
